Status:
COMPLETED
Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18-80 years
Brief Summary
This study was a real-life study which was based on secondary data collection from the electronic or paper medical records from the Dermatology Clinics of the 14 University, Training \& Research Hospi...
Detailed Description
The study was a retrospective, multicenter, cohort study which was based on data collection at week 4,16 and 52 of secukinumab treatment of moderate to severe plaque psoriasis. The observational desi...
Eligibility Criteria
Inclusion
- A diagnosis of psoriasis
- Age ≥ 18 years at registry baseline.
- Patients with a firm diagnosis of chronic plaque psoriasis for at least 6 months before enrollment
- Secukinumab treatment should be initiated 52 weeks before data collection date
- Moderate to severe plaque psoriasis with PASI score of ≥10 before initiating secukinumab.
Exclusion
- Patients diagnosed with others types of psoriasis (pustular psoriasis, erythrodermic psoriasis etc) are excluded.
- Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA
Key Trial Info
Start Date :
July 9 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2021
Estimated Enrollment :
277 Patients enrolled
Trial Details
Trial ID
NCT05344482
Start Date
July 9 2020
End Date
August 31 2021
Last Update
July 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
East Hanover, New Jersey, United States, 07936-1080